Skip to content

Nurix Therapeutics, Inc. NRIX Debt securities - current

Debt securities - current at other companies

Block logo
BlockXYZ
$462.61M+30.4%
Agilon Health logo
Agilon HealthAGL
$91.42M-60.3%
General Motors logo
General MotorsGM
$4.62B-33.3%
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
$199.37M-42.7%
Qualys, Inc. logo
Qualys, Inc.QLYS
$191.88M+27.7%
Nike logo
NikeNKE
$1.4B-22.0%

Other financials

Income statement

See full
Revenue$6.3M-66.1%
Operating income-$92.5M-47.1%
Net income-$87.2M-54.7%
EPS (diluted)-$0.79-17.9%

Balance sheet

See full
Cash & equivalents$72.2M-6.1%
Total debt$58.7M+120%
Total equity$480.9M0.0%
Total assets$636.1M+3.4%

Cash flow

See full
Operating cash flow-$71.9M-17.7%
CapEx$1.0M-70.0%
Free cash flow-$73.0M-13.0%

Valuation

See full
Market cap$1.95B+40.1%
Enterprise value$1.94B+45.1%
P/S27.2×+2.5×

Profitability

See full
Operating margin-439.3%+35.3pp
Net margin-411.4%+52.7pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-61.4%-2.5pp
Debt / equity0.1×+0.1×
Current ratio-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent.

The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s debt securities - current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s debt securities - current?
Nurix Therapeutics, Inc. (NRIX) reported debt securities - current of $469.54M in Q4 2025.
How has Nurix Therapeutics, Inc.'s debt securities - current changed year-over-year?
Nurix Therapeutics, Inc.'s debt securities - current decreased by 0.9% year-over-year, from $473.76M to $469.54M.
What is the long-term trend for Nurix Therapeutics, Inc.'s debt securities - current?
Over 2 years (2023 to 2025), Nurix Therapeutics, Inc.'s debt securities - current has grown at a 21.8% compound annual growth rate (CAGR), from $233.28M to $345.98M.